Pancreatic Ductal AdenocarcinomaSymptoms, Doctors, Treatments, Advances & More
Learn About Pancreatic Ductal Adenocarcinoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Jefferson Surgery - Honickman Center
Charles Yeo is an Oncologist and a General Surgeon practicing medicine in Philadelphia, Pennsylvania. Dr. Yeo is rated as an Elite provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Yeo is board certified in Surgery. Dr. Yeo is currently accepting new patients.
Skip Viragh Outpatient Cancer Center
Richard Burkhart, M.D., is an Associate Professor of Surgery at The Johns Hopkins Hospital with a focus on complex minimally-invasive surgery and research for cancers of the pancreas, liver and bile ducts. Dr. Burkhart received his medical degree from Boston University and completed his surgical residency and research fellowships at the Thomas Jefferson University Hospital in Philadelphia and the Cold Spring Harbor Laboratories. He is a member of several professional organizations, including the American Association of Cancer Research, the American College of Surgeons, the Society of Surgery for the Alimentary Tract, the Pancreas Club, and the Society of Surgical Oncology. Outside the operating room, Dr. Burkhart heads a multidisciplinary laboratory team dedicated to bringing next-generation precision medicine approaches into the routine clinical care of patients that we serve. He has a particular research interest in using personalized models of pancreas cancer, made from tumor during and immediately after surgical resection, to select the best chemotherapy for each patient to support long-term survival and improve rates of disease cure. The laboratory team, funded in part by the National Institutes of Health, the National Cancer Institute, the Lustgarten Foundation and Stand Up to Cancer, is also thankful to the many patients who have supported the work through philanthropic gift. Dr. Burkhart is rated as an Elite provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, Pancreatectomy, and Pancreaticoduodenectomy. Dr. Burkhart is board certified in American Board Of Surgery.
Susan Tsai is an Obstetrics and Gynecologist practicing medicine in Chicago, Illinois. Dr. Tsai is rated as an Elite provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. She is also highly rated in 7 other conditions, according to our data. Her clinical expertise encompasses Pancreatic Ductal Adenocarcinoma, Ampullary Cancer, Gallbladder Disease, Pancreatectomy, and Hepatectomy.
Summary: This is a clinical trial that tests a surgical treatment. Everyone in the study will get the same treatment, and there is no comparison or placebo group. Patients can join the study if they have pancreatic cancer that has spread to only a few spots in the liver or lungs. They must be receiving a type of chemotherapy called NALIRIFOX before surgery (this is called neoadjuvant chemotherapy). If the ...
Summary: The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease a...